Navigation Links
Depression Pipeline Market H2 2015 Review (87 Companies) Report
Date:3/14/2016

PUNE, India, March 14, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Depression - Pipeline Review, H2 2015" market research report to its store with comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Depression and special features on late-stage and discontinued projects.

Complete report on H2 2015 pipeline review of Depression with 152 market data tables and 17 figures, spread across 511 pages is available at http://www.rnrmarketresearch.com/depression-pipeline-review-h2-2015-market-report.html   

The report also reviews key players involved in the therapeutic development for Depression and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Depression Pipeline Review, H2 2015 report include AB Science SA, Acetylon Pharmaceuticals, Inc., Ache Laboratorios Farmaceuticos S/A , Adamed Sp. z o.o., Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc., Alkermes Plc, Allergan Plc, Alvogen Korea, Amorsa Therapeutics Inc., Anavex Life Sciences Corp., Angelini Group, Angita B.V., ANP Technologies, Inc., Ascendis Pharma A/S, AstraZeneca Plc, Azevan Pharmaceuticals, Inc., BioCrea GmbH, Bionomics Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Calico LLC, Cerecor Inc., Clera Inc., Convergence Pharmaceuticals Ltd., D-Pharm Ltd., Delpor, Inc., Domain Therapeutics SA, e-Therapeutics Plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, GliaCure Inc., H. Lundbeck A/S, Heptares Therapeutics Limited, HolsboerMaschmeyer NeuroChemie GmbH, Hua Medicine Ltd., Hyundai Pharmaceutical Co., Ltd., INSYS Therapeutics, Inc., Intas Pharmaceuticals Ltd., Intra-Cellular Therapies, Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., Johnson & Johnson, KemPharm, Inc., Lead Discovery Center GmbH, Luye Pharma Group Ltd., M et P Pharma AG, Mapreg S.A.S., Meta-IQ ApS, Methylation Sciences Inc., MI.TO. Technology S.r.L., miCure Therapeutics Ltd., Mitsubishi Tanabe Pharma Corporation, Neuralstem, Inc., Neurocrine Biosciences, Inc., NeuroNascent, Inc., NeurOp, Inc, Newron Pharmaceuticals S.p.A., Nippon Chemiphar Co., Ltd., nLife Therapeutics, S.L., Novartis AG, Omeros Corporation, Otsuka Holdings Co., Ltd., Pfizer Inc., Pherin Pharmaceuticals, Inc., Polleo Pharma Limited, Protagenic Therapeutics Inc., Reviva Pharmaceuticals Inc., Richter Gedeon Nyrt., RTI International, Saniona AB, SK Biopharmaceuticals Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., Suven Life Sciences Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Takeda Pharmaceutical Company Limited, Tetra Discovery Partners LLC, Teva Pharmaceutical Industries Limited, Trevena, Inc., Turing Pharmaceuticals AG , VistaGen Therapeutics , Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Zogenix, Inc. and Zysis Limited.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=454724  

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Depression and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities with key players involved in the therapeutics development for Depression and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects, review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Depression pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Another newly published market research report titled on Stroke - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Stroke Pipeline market research report of 563 pages is available at http://www.rnrmarketresearch.com/stroke-pipeline-review-h2-2015-market-report.html  

Explore more reports on Neurology therapeutics

About Us:   

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us:

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345


'/>"/>
SOURCE RnR Market Research
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Depression and Autism Reviewed by NeuroPerspective
2. American Psychiatric Association Task Force Report Identifies Potential Value of NeuroRx Active Ingredient for Treatment of Depression
3. Dr. Maurizio Fava, Internationally Renowned Expert in the Field of Depression, Joins VistaGens Clinical and Scientific Advisory Board
4. Iodine Announces Collaboration With Postpartum Progress To Help Find What Works Best For Women With Postpartum Depression
5. NeuroRx Announces First Human Trial Results Targeting Sustained Treatment of Bipolar Depression & Suicidality
6. Eight Studies Find Capnography, Pulse Oximetry Can Leave Patients at Risk for Life-Threatening Respiratory Depression
7. Integrative Medicine has Positive Impact on Patient Activation, Chronic Pain, Depression
8. Northeasterners Are Tougher Than Other Regions, According to Winter Depression Symptom Research from InCrowd
9. Studies Show Respiratory Motion Patient Monitor May be Early Warning System for Respiratory Depression
10. The Impact of Genericization in the Unipolar Depression Market Will be Tempered by the Continued Uptake of Novel Antidepressants and Antipsychotics
11. New MTHFR Gene Test Extends Holistic Pharmacogenomics Approach to Treating Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/31/2017)... MEMPHIS, Tenn. , July 31, 2017 Three Tru-D ... in Yongsan, South Korea . Tru-D, short for "Total ... patient and operating rooms after an environmental services (ES) professional cleans the ... ... "Although ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... 2017 , ... Pivot Point Consulting, a ... the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects of ... clients with initial vendor selection and pre-implementation planning through go-live support and post-live ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a captivating and ... named Edward Koontz. “To Walk Away” is the creation of published author, Larry R. ... two hundred manuscripts in chemistry and religion, as well as four novels. , ...
(Date:8/22/2017)... Carolina (PRWEB) , ... August 22, 2017 , ... ... advisor. Mr. Stewart is the Founder and Managing Member for t4 Leadership Development ... have become critical to his definition of “success”: physician leadership development, servant leadership, ...
(Date:8/21/2017)... Yorba Linda, Ca (PRWEB) , ... August 22, ... ... for numerous industries, but not without risk to health and safety. By learning ... risks could be eliminated. , In this webinar, attendees will gain a ...
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior assisted living ... Center. , Guests will be able to vote for their favorite Chef among ... with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice ...
Breaking Medicine News(10 mins):